Their clinical relevance in gastric and colon cancers stems from their frequent dysregulation, often driven by genetic alterations (e.g., KRAS, BRAF, PIK3CA, PTEN, and mTOR), which leads to constitutive activation and fosters uncontrolled cancer cell growth and survival. This evidence concerns the gene MTOR and malignant colon neoplasm.